Pressrelease

Uppsala 24th  January 2020

Nanexa signs a “Technology Evaluation Agreement” with a global  equipment company for technology evaluation and upscaling of the PharmaShell® process.

Nanexa has entered into a collaboration with a global  equipment company for upscaling and technology evaluation of PharmaShell®, and to evaluate the conditions for a more extensive collaboration.

The companies have signed a “Technology Evaluation Agreement” that regulates the scope of the evaluation, ownership of evaluation results and also describes ownership of any potential patent opportunities that may arise. Each party will bear its own costs during the evaluation, which is expected to start in early 2020.

 

The company’s CEO David Westberg comments: 

The ability to produce PharmaShell® on a commercial scale is crucial to being able to develop and market new drugs with our technology. Upscaling is something we have already worked on in our pilot plant, and if this collaboration is successful, it will speed up that process considerably.

The evaluation can also potentially provide important information to companies we are already working with, as well as new pharmaceutical companies that we have a dialogue with regarding future collaborations and product development. I see many possible synergies with the equipment company and look forward to getting started on the evaluation together with this very knowledgeable team.

 

For further information:

Nanexa AB (publ)

David Westberg, VD

Phone: +46 709 42 83 03

E mail: david.westberg@nanexa.se

www.nanexa.com

 

About Nanexa AB (publ)

Nanexa AB is a nanotechnology drug delivery company focusing on the development of PharmaShell®, which is a new and groundbreaking drug delivery system that is expected to have great potential in a number of medical indications. Within the framework of PharmaShell®, Nanexa has partnership agreements with among others, AstraZeneca.